What “loss of exclusivity” means for Crysvita
Crysvita (burosumab) is a biologic used for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). “Loss of exclusivity” generally refers to the time when the legal protections that keep competitors from marketing an equivalent product end, allowing biosimilar or similar biologics to enter without needing to rely solely on the originator’s clinical trial data. The exact timing depends on the country and the specific patents and regulatory exclusivities in force for each indication.
When does Crysvita lose exclusivity?
The provided information does not include the specific country, indication (XLH vs TIO), or a patent/exclusivity calendar for Crysvita. Without that, the exact “loss of exclusivity” date can’t be stated accurately.
If you tell me the country (for example, US, EU, UK, Japan) and which condition you mean (XLH or TIO), I can narrow the answer to the relevant exclusivity windows for that market and use the correct legal framework (patents, data exclusivity, and any biosimilar-related provisions).
Can biosimilars launch immediately when exclusivity ends?
Usually not in a single step. Even after exclusivity ends, biosimilar entry can be shaped by:
- remaining patents (newer or secondary patents can still block specific claims),
- how regulators interpret interchangeability/similarity requirements,
- and whether a biosimilar company has already obtained approval but cannot market until protections expire.
So “loss of exclusivity” is often the start of competitive risk, not an automatic immediate launch.
Which protections matter most for loss of exclusivity (patents vs regulatory exclusivity)?
For biologics, “exclusivity” is often a mix of:
- patent protection (can extend beyond data exclusivity if there are additional patents),
- data protection/exclusivity periods under drug-approval rules,
- and, depending on jurisdiction, requirements and timelines for biosimilar applicants.
The practical question for patients and payers is when a payer can buy a non-originator version without legal risk.
How to find the exact loss-of-exclusivity date for Crysvita (what to look up)
To get the correct date, you typically need:
1. the jurisdiction (US vs EU vs UK etc.),
2. the indication (XLH vs TIO),
3. the product marker used by the local regulator or guidance (biosimilar pathways differ),
4. the “earliest expiring” listed protections (patents and regulatory exclusivities).
If you share your country and indication, I can structure the lookup around those specifics.
Quick clarifying question
Which market do you mean by “loss of exclusivity” (US, EU, UK, or another country), and for which Crysvita use case (XLH or TIO)?